SG/CALL/MODERNA/130/0.1/20.09.24 | Market Closed - Euronext Paris 17:30:01 19/06/2024 BST | ||
| 1.545 EUR | -9.65% |
|
| Current month | -33.69% | ||
| 1 month | -11.46% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 1.545 | -9.65% |
| 18/06/24 | 1.71 | -14.50% |
| 17/06/24 | 2 | -1.96% |
| 14/06/24 | 2.04 | -17.07% |
| 13/06/24 | 2.46 | -5.38% |
Real-time Euronext Paris
Last update June 19, 2024 at 05:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 2J45S | |
| ISIN | DE000SW9PK76 |
| Date issued | 29/04/2024 |
| Strike | 130 $ |
| Maturity | 20/09/2024 (93 Days) |
| Parity | 10 : 1 |
| Emission price | 0.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.34 € |
|---|---|
| Lowest since issue | 0.795 € |
| Spread | 0.03 € |
| Spread % | 1.92% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Warrants
- 2J45S Warrant
